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FOR THE DIAD STUDY INVESTIGATORS*
OBJECTIVE — Toestimatebaselinecardiovascularriskof1,123participantsintheDetection
of Ischemia in Asymptomatic Diabetics (DIAD) study and to assess cardiac event rates and the
effect of screening on outcomes in these higher-risk participants.
RESEARCH DESIGN AND METHODS — Baseline cardiovascular risk was assessed
using four established methods: Framingham score, UK Prospective Diabetes Study (UKPDS)
risk engine, criteria of the French-Speaking Association for the Study of Diabetes and Metabolic
Diseases, and the presence or absence of metabolic syndrome. Cardiac events (cardiac death or
nonfatal myocardial infarction) were assessed during the 4.8-year follow-up in participants with
intermediate/high cardiovascular risk.
RESULTS — By various risk-stratiﬁcation approaches, 53–75% of participants were deﬁned
as having intermediate or high cardiovascular risk. The prevalence of inducible ischemia on
screening in these individuals ranged from 21 to 24%, similar to lower-risk participants (19–
23%). Cardiac event rates were greater in intermediate-/high-risk versus low-risk groups, but
thiswasonlysigniﬁcantfortheUKPDSriskengine(4.2vs.1.2%,P0.002).Theannualcardiac
event rate was 1% in all risk groups, except in the high-risk UKPDS group (2% per year). In
intermediate-/high-risk participants randomized to screening versus no screening, 4.8-year car-
diac event rates were similar (2.5–4.8% vs. 3.1–3.7%).
CONCLUSIONS — A substantial portion of the DIAD population was deﬁned as having
intermediate/high baseline cardiovascular risk. Nevertheless, their annual cardiac event rate was
low and not altered by routine screening for inducible ischemia.
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I
n the Detection of Ischemia in Asymp-
tomatic Diabetics (DIAD) study, 1,123
asymptomatic individuals with type 2
diabetes were randomized to either
screening with stress myocardial perfu-
sion imaging (MPI) or no screening. The
prevalence of inducible ischemia was as-
sessed and the hypothesis that screening
would have a favorable effect on outcome
was tested. The results of the DIAD study
have been published (1–3). The preva-
lenceofabnormalMPIwasnotonlylower
than anticipated at 22% of participants,
but, in addition, only 6% of participants
had clinically signiﬁcant inducible isch-
emia and another 6% had adenosine-
induced ischemic electrocardiogram
changes(1).Thecumulative4.8-yearcar-
diac event rate (cardiac death and nonfa-
tal myocardial infarction) was low (2.9%
overall or 0.6% per year) (3). Moreover,
there was no signiﬁcant difference in car-
diac outcomes between participants who
were randomized to screening versus no
screening. These favorable outcomes
were unexpected when compared with
historical outcomes data in patients with
type 2 diabetes (4,5). One possible expla-
nation for these ﬁndings could be that the
DIAD population was at relatively low
baseline cardiovascular risk and therefore
not representative of the general type 2
diabetic population.
To place the DIAD cohort into clear
perspective, a post hoc analysis of base-
line cardiovascular risk was performed
using four well-known risk-stratiﬁcation
approaches, including the Framingham
risk score (6), the UK Prospective Diabe-
tes Study (UKPDS) risk engine (7), high-
risk criteria as deﬁned by the French-
Speaking Association for the Study of
Diabetes and Metabolic Diseases (ALFE-
DIAM) and the French Society of Cardi-
ology (SFC) (8), and the presence of
metabolic syndrome as deﬁned by the In-
ternationalDiabetesFederationTaskforce
(9). The prevalence of abnormal screen-
ing, cardiac event rates and the effect of
screening on outcomes were analyzed in
participants stratiﬁed as having interme-
diate/high cardiovascular risk (Fig. 1).
RESEARCH DESIGN AND
METHODS— Methods of recruit-
ment and randomization as well as the
demographics of the DIAD study have
been published (1). Participants were re-
cruited from 14 diabetes clinics in the
U.S. and Canada. Inclusion criteria were
type 2 diabetes, age 50–75 years, and no
symptoms or clinical signs suggestive of
coronary artery disease (CAD). Exclusion
criteria included angina pectoris; stress
test or coronary angiography within the
previous 3 years; history of myocardial
infarction, heart failure, or coronary re-
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diogram; any current clinical indication
for stress testing; active bronchospasm;
and limited life expectancy due to
comorbidity.
The participants were randomized to
screening with an adenosine vasodilator
Tc-99m-Sestamibi MPI (n  561) or no
screening(n562)(1).Afterrandomiza-
tion,treatmentwasatthediscretionofthe
participant’s physician. The protocol was
approved by the institutional review
boards. Details of the stress testing and
MPI interpretation have been described
(1,2). All participants had follow-up for 5
years (3).
Post hoc risk stratiﬁcation
The DIAD participants were risk-
stratiﬁed as follows:
1) Framingham risk score: On the ba-
sisofage,sex,lipidlevels,bloodpressure,
smoking, and presence of diabetes, the
participants were categorized as having
either a low (10%), intermediate (10–
20%), or high (20%) 10-year risk for
symptomatic CAD (6). Participants with
intermediate or high Framingham risk
scores were deﬁned as having a higher
riskandwerecomparedwiththelow-risk
group.
2)UKPDSriskengine:Onthebasisof
age, sex, duration of diabetes, smoking,
systolic blood pressure, total cholesterol,
HDL,ethnicity,andA1C,theparticipants
were classiﬁed into three UKPDS risk cat-
egories: low (14%), intermediate (15–
30%), or high (30%) 10-year risk for
CAD (7). Participants with an intermedi-
ate or high UKPDS risk score were de-
ﬁned as having a higher risk and were
compared with the low-risk group.
3) ALFEDIAM/SFC high-risk criteria:
The ALFEDIAM recommended screening
for inducible myocardial ischemia in pa-
tients with type 2 diabetes (8) with one of
the following: age 60 years; duration of
diabetes 10 years and at least two other
cardiovascular risk factors; peripheral ar-
terial disease; and proteinuria and mi-
croalbuminuria with at least two other
cardiovascular risk factors. Participants
meeting one of these criteria were deﬁned
as the higher-risk cohort.
4) Metabolic syndrome: Metabolic
syndrome was deﬁned by at least three of
ﬁve criteria deﬁned by the International
Diabetes Federation Taskforce (9) and
was considered to represent higher car-
diovascular risk (10,11). The criteria in-
cludedwaistcircumference102cm(for
men) or 88 cm (for women), triglycer-
ides 150 mg/dl, HDL 40 mg/dl (for
men) or 50 mg/dl (for women), systolic
blood pressure 130 mmHg and/or dia-
stolic blood pressure 85 mmHg, and
fasting glucose 100 mg/dl. Participants
with metabolic syndrome were deﬁned as
having a higher risk; their outcome was
compared with the cohort without meta-
bolic syndrome.
Statistical analysis
Theparticipantswereriskstratiﬁedbased
on clinical variables documented at en-
rollment into the study. Because it is gen-
erallyagreedthatlow-riskpatientsshould
not undergo specialized cardiac testing
(12), only participants deﬁned as having
an intermediate/high risk were analyzed
for outcomes according to randomiza-
tion. Primary end points were nonfatal
myocardial infarction and cardiac death.
Secondary end points included unstable
angina,heartfailure,stroke,andcoronary
revascularization(3).Therateofcoronary
revascularization was analyzed sepa-
rately. Of 561 participants randomized to
screening, 522 underwent screening and
39 did not. The latter participants were
analyzed on an intention-to-screen basis.
Statistical analysis was performed
with Minitab 15 statistical software
(Minitab, State College, PA). Cardiac out-
comes were compared in low-risk versus
intermediate-/high-risk groups and in in-
termediate-/high-risk participants ran-
domized to screening versus no
screening. The Fisher exact test was used
to compare the prevalence of abnormal
MPI. The log-rank test was used for com-
paringcardiacoutcomesbetweengroups.
Cox proportional hazards regression was
computed using COXPH in R (www.r-
project.org) in order to determine hazard
ratios(HRs)comparingeventsinlow-risk
versus intermediate-/high-risk groups
and in screened versus not screened
high-/intermediate-risk participants.
RESULTS
Framingham risk score
Overall,283(25%)participantswouldbe
deﬁnedashavinglowrisk,and840(75%)
as having intermediate (542 [48%]) or
high(298[27%])cardiovascularrisk(Ta-
ble 1). Of 522 screened participants, 387
(74%) were deﬁned as having intermedi-
ate/high risk. The prevalence of abnormal
MPI in the screened intermediate-/high-
risk versus screened low-risk groups was
similar (21 vs. 23%, P  0.72) (Table 2).
Primaryandsecondarycardiaceventsand
coronary revascularizations are shown in
Table 1. Overall, primary cardiac events
trended to be higher in the intermediate-/
high-riskgroupversusthelow-riskgroup
(28 [3.3%] vs. 4 [1.4%], P  0.09). How-
ever, primary cardiac event rates in 418 in-
termediate-/high-risk participants
randomized to screening and in the 422 in-
termediate-/high-risk participants random-
Figure 1—Flow diagram of the post hoc analysis of the DIAD data. Cardiac outcomes were
reanalyzed in the not-low-risk participants who were randomized to no screening versus
screening.
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3.6%; log rank P  0.71) Table 3).
UKPDS risk engine
Because of missing data, 19 participants
could not be categorized by the UKPDS
risk engine. Of the remaining 1,104 par-
ticipants, 515 (47%) were categorized as
low risk and 589 (53%) as intermediate
(447 [40.5%]) or high (142 [13%]) risk
(Table 1). Of those screened, 276 (53%)
were at intermediate/high risk (Table 2).
The prevalence of abnormal MPI in inter-
mediate-/high-risk and low-risk partici-
pants was not different (24 vs. 19%, P 
0.2) (Table 2). However, the incidence of
primary cardiac events was higher in the
intermediate-/high-risk group compared
with the low-risk group (25 [4.2%] vs. 6
[1.2%], P  0.002) (Table 1). Primary
cardiac event rates were similar in 291
intermediate-/high-risk participants ran-
domizedtoscreeningandin298interme-
diate-/high-risk participants randomized
to no screening (4.8 vs. 3.7%, log rank
P  0.51) (Table 3).
ALFEDIAM/SFC high-risk criteria
Of 1,123 participants, 713 (63%) met
ALFEDIAM/SFC high-risk criteria (Table
1). Of 522 screened participants, 326
(62%) were high risk (Table 2). The prev-
alence of abnormal MPI in high-risk and
low-risk participants was not different
(23 vs. 19%, P  0.27) (Table 2). The
incidence of primary cardiac events was
not different in the high- and low-risk
groups(24[3.4%]vs.8[2.0%],P0.19)
(Table 1), but secondary event rates were
higher in the high-risk than in the low-
Table 1—Cardiac events in risk groups according to various risk stratiﬁcation schemes
Low risk
Intermediate
risk High risk
Intermediate/
high risk P* HR (95% CI)
Framingham score
n 283 542 298 840
Primary cardiac events 4 (1.4) 14 (2.6) 14 (4.7) 28 (3.3) 0.09 2.4 (0.84–6.85)
Secondary cardiac events 5 (1.8) 15 (2.8) 15 (5.0) 30 (3.6) 0.12 2.07 (0.80–5.34)
Revascularizations 9 (3.2) 40 (7.4) 26 (8.7) 66 (7.9) 0.006 2.57 (1.28–5.16)
UKPDS risk engine
n 515 447 142 589
Primary cardiac events 6 (1.2) 11 (2.5) 14 (9.9) 25 (4.2) 0.002 3.65 (1.50–8.90)
Secondary cardiac events 12 (2.3) 16 (3.6) 7 (4.9) 23 (3.9) 0.13 1.70 (0.84–3.41)
Revascularizations 18 (3.5) 39 (8.7) 17 (12.0) 56 (9.5) 0.0001 2.80 (1.65–4.77)
ALFEDIAM/SFC criteria
n 410 713
Primary cardiac events 8 (2.0) 24 (3.4) 0.19 1.71 (0.77–3.80)
Secondary cardiac events 5 (1.2) 30 (4.2) 0.01 3.46 (1.34–8.91)
Revascularizations 22 (5.4) 53 (7.4) 0.21 1.38 (0.84–2.26)
Metabolic syndrome No Yes
n 319 804
Primary cardiac events 8 (2.5) 24 (3.0) 0.67 1.19 (0.54–2.65)
Secondary cardiac events 8 (2.5) 27 (3.4) 0.46 1.35 (0.61–2.96)
Revascularizations 21 (6.6) 54 (6.7) 0.9 1.03 (0.62–1.71)
Data are n (%), unless otherwise indicated. *P values are shown for low risk versus intermediate/high risk for Framingham and UKPDS; low risk versus high risk for
ALFEDIAM/SFC; no versus yes for metabolic syndrome.
Table 2—Results of stress MPI in 522 participants randomized to screening, grouped according to various risk stratiﬁcation schemes
Total normal
MPI
Total
abnormal MPI
Non-MPI
abnormalities
Small
defect
Moderate/large
defect
Framingham score
Low risk (n  135) 104 (77.0) 31 (23.0) 9 (6.7) 14 (10.4) 8 (5.9)
Intermediate/high risk (n  387) 305 (78.8) 82 (21.2), P  0.72 21 (5.4) 36 (9.3) 25 (6.5)
UKPDS risk engine
Low risk (n  241) 195 (80.9) 46 (19.1) 14 (5.8) 20 (8.3) 12 (5.0)
Intermediate/high risk (n  276) 210 (76.1) 66 (23.9), P  0.2 16 (5.8) 30 (10.9) 20 (7.3)
ALFEDIAM/SFC criteria
Low risk (n  196) 159 (81.1) 37 (18.9) 6 (3.1) 17 (8.7) 14 (7.1)
High risk (n  326) 250 (76.7) 76 (23.3), P  0.27 24 (7.4) 33 (10.1) 19 (5.8)
Metabolic syndrome
No (n  157) 120 (76.4) 37 (23.6) 11 (7.0) 18 (11.5) 8 (5.1)
Yes (n  365) 289 (79.2) 76 (20.8), P  0.49 19 (5.2) 32 (8.8) 25 (6.9)
Dataaren(%).Atotalof19participantsnotcategorizedduetomissingdata.PvaluesreﬂectcomparisonoftotalabnormalMPIintworiskgroups(seetext).Non-MPI
abnormalities  ischemic electrocardiogram changes during adenosine infusion, transient ischemic dilation, or baseline left ventricular dysfunction.
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0.01) (Table 1). However, the primary
cardiac event rates were similar in 352
high-risk participants randomized to
screening and 361 high-risk participants
randomized to no screening (3.7 vs.
3.1%, log rank P  0.61) (Table 3).
Metabolic syndrome
Of all participants, 804 (72%) had meta-
bolic syndrome (Table 1). Of 522
screened participants, 365 (70%) had
metabolic syndrome (Table 2). The prev-
alence of abnormal MPI in participants
with versus without metabolic syndrome
was not different (21 vs. 24%, P  0.49)
(Table 2). Overall, primary cardiac event
rates were similar in both groups (meta-
bolic syndrome 24 [3.0%] vs. no meta-
bolic syndrome 8 [2.5%], P  0.67)
(Table 1). Primary cardiac event rates in
398 participants with metabolic syn-
drome randomized to screening and in
406 participants with metabolic syn-
drome randomized to no screening were
similar (2.5 vs. 3.5%, log rank P  0.42)
(Table 3).
CONCLUSIONS — This post hoc
analysis provides an important perspec-
tive on the results of the DIAD study (3)
bydemonstratingthatthemajorityofpar-
ticipants were categorized as being either
at intermediate or high cardiovascular
risk according to four commonly used
cardiac risk-stratiﬁcation schemes. The
UKPDS risk engine, speciﬁcally designed
for type 2 diabetic patients, appeared to
best predict the occurrence of cardiac
events in DIAD participants. In contrast,
risk stratiﬁcation did not predict the re-
sults of screening-stress MPI. The study
was not powered to determine the effect
ofscreeningonoutcomesinthesubgroup
of DIAD participants categorized as hav-
ing higher risk; such analysis would have
requiredathree-tofourfoldlargersample
size.However,screeninghadnoapparent
beneﬁt on outcomes in the subgroups as
deﬁned by these four separate stratiﬁca-
tion schemes.
This analysis expands upon our pre-
vious ﬁnding that the overall cardiac
event rate in asymptomatic patients with
type 2 diabetes is lower in the current era
than might be predicted based on histor-
ical data. Speciﬁcally, it shows that the
purportedly higher-risk subgroups actu-
ally had lower event rates than were pre-
dicted by either the Framingham or
UKPDSscores.Theaverageannualriskof
participants in the combined intermedi-
ate-/high-risk Framingham group was
lower (0.6% per year) than predicted
(1–2% per year for intermediate risk and
2% per year for high risk). Similarly, in
the combined intermediate-/high-risk
UKPDS groups, the risk was also lower
(0.8% per year) than predicted (interme-
diate 1.5–3% per year and high risk 3%
per year). Thus, even these higher-risk
participants had observed cardiac event
rates that would traditionally been con-
sidered to be low risk. Only a small sub-
group of 142 high-risk participants
deﬁned by the UKPDS risk engine had an
event rate of 2% per year (Table 1),
which might have warranted more ag-
gressive risk-reduction strategies. Al-
though 14 of these high-risk participants
had primary cardiac events, it is impor-
tanttonotethatthemajorityofevents(17
of 31) occurred in participants who were
not categorized as high risk according to
the UKPDS engine (Table 1).
The observation that cardiac event
rates in the DIAD were lower than pre-
dicted by either the Framingham score or
the UKPDS risk engine likely reﬂects the
fact that these scoring schemes are based
Table 3—Cardiac events in intermediate-/high-risk participants randomized to no screening versus screening
Framingham score: intermediate/high risk (n  840)
P HR (95% CI) No screening (n  422) Screening (n  418)
Primary cardiac events 15 (3.6) 13 (3.1) 0.71 0.87 (0.41–1.83)
Secondary cardiac events 13 (3.1) 17 (4.1) 0.45 1.32 (0.64–2.72)
Revascularizations 41 (9.7) 25 (6.0) 0.05 0.61 (0.37–1.01)
UKPDS risk engine: intermediate/high risk (n  589)
No screening (n  298) Screening (n  291)
Primary cardiac events 11 (3.7) 14 (4.8) 0.51 1.30 (0.59–2.86)
Secondary cardiac events 11 (3.7) 12 (4.1) 0.79 1.12 (0.49–2.53)
Revascularizations 31 (10.4) 25 (8.6) 0.48 0.83 (0.49–1.4)
ALFEDIAM/SFC criteria: high risk (n  713)
No screening (n  361) Screening (n  352)
Primary cardiac events 11 (3.1) 13 (3.7) 0.61 1.23 (0.55–2.75)
Secondary cardiac events 12 (3.3) 18 (5.1) 0.21 1.59 (0.77–3.31)
Revascularizations 31 (8.6) 22 (6.3) 0.27 0.74 (0.43–1.27)
Metabolic syndrome: yes (n  804)
No screening (n  406) Screening (n  398)
Primary cardiac events 14 (3.5) 10 (2.5) 0.42 0.72 (0.32–1.62)
Secondary cardiac events 12 (3.0) 15 (3.8) 0.55 1.26 (0.59–2.70)
Revascularizations 31 (7.6) 23 (5.8) 0.31 0.76 (0.44–1.3)
Data are n (%), unless otherwise indicated.
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1990s (13,14). In the intervening years,
the awareness of cardiovascular risk in
type 2 diabetes has grown (15), and pri-
mary cardiac prevention measures have
been widely endorsed and implemented
(16). In the DIAD study, the majority of
participants were aggressively treated
with statins, ACE inhibitors, and aspirin
(3). One might hypothesize that these in-
terventions prevented cardiac events in
the higher-risk DIAD participants. Rather
than concluding from this analysis that
diabetes does not confer signiﬁcant car-
diacrisk,itismoreappropriatetoempha-
sizethepotentialbeneﬁtofcontemporary
medical therapy on the outcomes of these
patients.
Ourﬁndingshaveimportantimplica-
tions for the utilization of cardiac screen-
ing in asymptomatic diabetic patients.
The2009AppropriateUseCriteriaforCar-
diacRadionuclideImaging,issuedbyacon-
sortium of professional societies (12),
considered asymptomatic diabetic pa-
tients to be a special group in whom
screening was appropriate based on their
historically high risk for cardiovascular
complications, equivalent to that of pa-
tients with established CAD (16,17). The
results of the present analysis raise ques-
tionsabouttheappropriatenessofscreen-
ing asymptomatic patients with diabetes
who are treated with contemporary risk
factor–modifying therapies. They further
suggest that existing guidelines warrant
revision.
One interesting observation in the
current analysis is that none of the strati-
ﬁcation schemes predicted abnormalities
onscreening-stressMPI.Neitherthepres-
ence nor severity of MPI abnormalities
was greater in the higher-risk patients.
Thereasonsforthisﬁndingareuncertain,
but this lack of correlation reduces the
potential impact of screening strategies
based on existing clinical risk stratiﬁca-
tion. For example, since the UKPDS risk
engine predicts outcome but not MPI
screening results, there would be patients
whomightscreennegativebutstillwould
be at risk for events. In the DIAD study,
although moderate/large MPI abnormali-
ties were predictive of cardiac events, nu-
merically more than half of the events
occurred in the larger cohort of patients
with negative screening (3).
We did not observe an effect of
screening on cardiac events in any of the
intermediate-/high-risk subgroups. Thus,
these results buttress the original conclu-
sion of the DIAD study that screening for
inducible ischemia cannot be currently
advocated in asymptomatic patients with
type 2 diabetes. However, because of the
limitednumberofsubjects,wecannotex-
clude the possibility that a larger study
speciﬁcally screening a high-risk sub-
group might come to a different conclu-
sion in support of screening.
It is important to point out that this
posthocanalysishasinherentlimitations.
Most notably, the DIAD study was de-
signed to include asymptomatic patients
with diabetes regardless of additional
clinical risk factors (1). Because of the rel-
atively small number of participants at
higher cardiovascular risk, the subgroup
analyses have insufﬁcient power to make
deﬁnitive statistical conclusions as to
whether screening leads to strategies that
improve cardiac outcomes. Furthermore,
theDIADcohortwasrepresentativeofthe
North American population mix that re-
ceivedaggressiveprimarycardiacpreven-
tion. Thus, generalization to other
countries with different ethnicities and
different approaches to diabetes care
might not be appropriate.
Inconclusion,asubstantialportionof
theDIADpopulationwouldbedeﬁnedby
commonly used risk-stratiﬁcation
schemes as being at intermediate/high
cardiovascular risk. Nevertheless, even in
these higher-risk participants, the annual
cardiaceventrateswerelowandoutcome
was not affected by routine screening for
inducible ischemia. Current guidelines
for routine cardiovascular screening in
asymptomatic patients with diabetes re-
quire reconsideration.
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